HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (11) Citing Articles via Google Scholar Google Scholar Articles by Fritzsche, S Articles by Schulz, W A Search for Related Content PubMed PubMed Citation Articles by Fritzsche, S Articles by Schulz, W A

Department of Urology, Heinrich-Heine University, Düsseldorf, Moorenstr. 5, 40225 Düsseldorf, Germany
¹ Department of Cellular and Molecular Pathology, German Cancer Research Centre, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
² Department of Pathology, Heinrich-Heine University, Düsseldorf, Germany

(Requests for offprints should be addressed to W A Schulz; Email: wolfgang.schulz{at}uni-duesseldorf.de)

Sprouty proteins encoded by the SPRY genes act as modulators and feedback inhibitors of signalling by epidermal growth factor (EGF) and fibroblast growth factor (FGF). Overactivity of EGF and FGF signalling common in prostate cancer might therefore be exacerbated by Sprouty down-regulation. Indeed, down-regulation of SPRY1 and SPRY2 expression has been independently reported. We found both genes modestly down-regulated by microarray expression analysis of microdissected prostate cancers and by quantitative RT-PCR in macrodissected specimens compared with benign tissues. Importantly, the decreases paralleled each other and expression levels of both genes were significantly lower in cancers that recurred within the average follow-up period of 32 months. In contrast to a previous report, no hypermethylation was found to accompany down-regulation of SPRY2 in cancer tissues and cell lines. We additionally investigated the expression of an SPRY1 alternative transcript presumed to be specific for fetal tissues and found its expression moderately well correlated with expression of the standard transcript through diverse tissues and cell lines. The present study confirms and extends previous reports by demonstrating concomitant down-regulation and a significant association with recurrence of SPRY genes.

This article has been cited by other articles:

				F. Edwin, K. Anderson, C. Ying, and T. B. Patel Intermolecular Interactions of Sprouty Proteins and Their Implications in Development and Disease Mol. Pharmacol., October 1, 2009; 76(4): 679 - 691. [Abstract] [Full Text] [PDF]

				S. C. Brady, M. L. Coleman, J. Munro, S. M. Feller, N. A. Morrice, and M. F. Olson Sprouty2 Association with B-Raf Is Regulated by Phosphorylation and Kinase Conformation Cancer Res., September 1, 2009; 69(17): 6773 - 6781. [Abstract] [Full Text] [PDF]

				M. J. Frank, D. W. Dawson, S. J. Bensinger, J. S. Hong, W. M. Knosp, L. Xu, C. E. Balatoni, E. L. Allen, R. R. Shen, D. Bar-Sagi, et al. Expression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomas Blood, March 12, 2009; 113(11): 2478 - 2487. [Abstract] [Full Text] [PDF]

				P. Lito, B. D. Mets, S. Kleff, S. O'Reilly, V. M. Maher, and J. J. McCormick Evidence That Sprouty 2 Is Necessary for Sarcoma Formation by H-Ras Oncogene-transformed Human Fibroblasts J. Biol. Chem., January 25, 2008; 283(4): 2002 - 2009. [Abstract] [Full Text] [PDF]